Allergan to co-promote Levadex with MAP

Assuming that MAP Pharmaceuticals’ Levadex inhaled dihydroergotamine for the treatment of migraine receives FDA approval, Allergan will market the product to pain specialists and neurologists in the US. MAP will handle marketing to primary care physicians in the United States and will retain all rights outside the US. MAP plans to submit an NDA for Levadex by the middle of 2011. Read the company’s press release.

Share

published on

December 9-December 11: DDL 2026, Edinburgh, Scotland

April 27-30: RDD Europe 2027, Antibes, France

May 30-June 2: ISAM Congress 2027, Dublin, Ireland

June 23: SMI London, London, UK